The following summarizes GlaxoSmithKline?s [NYSE: GSK] presentation of data on Avandia? (rosiglitazone maleate) to an Advisory Committee of the Food and Drug Administration (FDA) on July 30, 2007.
This is an analysis of existing data that has been previously published (online in Diabetes Care, 29 May 2007) and provides no new information on the risk of heart failure associated with the thiazolinediones (TZD) class.
A class of drugs commonly used to treat type 2 diabetes may double the risk of heart failure, according to a new analysis by researchers at Wake Forest University School of Medicine and colleagues.
A type 2 diabetes drug taken orally and in widespread use for more than a decade has been found to have distinct advantages over nine other, mostly newer medications used to control the chronic disease, according to a study by researchers at Johns Hopkins.
People wondering about excessive weight gain might look to their relationships with family and friends for one clue, suggests new research reported July 26, 2007, in The New England Journal of Medicine.
One route to a long and healthy life may be establishing the right balance in insulin signaling between the brain and the rest of the body, according to new research from Children’s Hospital Boston.
Obesity, the metabolic syndrome, and type 2 diabetes are frequently characterized by insulin resistance ? a condition in which normal amounts of insulin are not adequate to produce a normal insulin response from fat, muscle, and liver cells.
There are no high quality data to assess how well dietary treatments for type 2 diabetes work in people who have just been told they have the disease, but there is evidence that taking on exercise seems to be one way of improving blood sugar levels, according to the findings of a Cochrane Systematic Review.
Little evidence supports using rosiglitazone (Avandia) to improve the quality or length of life among adults with diabetes, according to a systematic review of data by German researchers.
Scientists have moved a step closer to understanding how our genetic make-up can lead us to develop heart disease and to predicting who is most at risk.